JOHNSON & JOHNSON WKN: 853260 ISIN: US4781601046 Forum: Aktien Thema: Hauptdiskussion

130 denke ich Ende des Jahres durchaus möglich

Der Impfstoffkandidat von Johnson & Johnson namens JNJ-78436735 unterscheidet sich technisch etwas von den übrigen Projekten. Er basiert auf einer von der Tochterfirma Janssen entwickelten Impfung gegen das Ebolavirus, die bereits von der EU zugelassen wurde. Auf derselben Plattform entwickelt die Firma auch Impfstoffe gegen weitere Virusinfektionen wie Zika, RSV und HIV.

Hier nochmal die deutsche Version. Sehr erfreuliche Nachrichten

https://amp2.handelsblatt.com/unternehmen/industrie/pharmabranche-johnson-und-johnson-will-corona-impfstoff-schon-anfang-2021-auf-den-markt-bringen/26210736.html

naja gregson, es nervt einfach wenn zu jeder aktie immer die dividendenfragen kommen. is ja echt nichts dabei mal zu googeln

Tommy du schwartlappen, bist ja sicher der super investor, es war lediglich eine Frage, nicht mehr und nicht weniger

Lol alles Profis hier...

Dividende fällt in Euro niedriger aus wegen Wechselkurse. Dividende wurde nicht gekürzt.

Wie kommst du denn drauf? Quelle?

Gab es hier eine Kürzung der Dividende?

Fällt einfach nicht hier.

Mal schauen, was heute bzw diese Woche so passiert!

.

Mich auch. Warte auf eine günstige Nachkaufmöglichkeit. Dann werde ich noch warten.

Wundert mich, dass das die Aktie nicht mehr belastet...

HEALTHCARE & PHARMA SEPTEMBER 17, 20205:12 PMUPDATED AN HOUR AGO Johnson & Johnson charged by New York with civil insurance fraud over opioid claims By Jonathan Stempel NEW YORK (Reuters) - New York state filed civil charges on Thursday accusing Johnson & Johnson of insurance fraud for downplaying the risks of opioid painkillers, including to doctors and elderly patients. Slideshow ( 2 images ) J&J and its Janssen Pharmaceuticals affiliate were accused of targeting elderly patients for opioid treatment despite the risks of side effects such as falls, fractures and neuropsychiatric symptoms. The company was also accused of employing marketing materials, “seemingly independent” advocacy groups and “key opinion leaders” to dismiss opioid addiction as a myth. “Misrepresentation of opioids to consumers for profit is inexcusable,” Governor Andrew Cuomo said in a statement. In a statement, J&J called its marketing and promotion of opioids “appropriate and responsible. Janssen provided these medicines for doctors treating patients suffering from pain and worked with regulators to provide appropriate information about their risks and benefits.” The charges by New York’s Department of Financial Services are the fourth in its opioid industry probe, following charges against Teva Pharmaceutical Industries Ltd and Allergan Plc, Endo International Plc and Mallinckrodt Plc. J&J, based in New Brunswick, New Jersey, has proposed paying $4 billion to settle opioid claims by U.S. states, cities and counties. It is separately appealing a $465 million judgment in Oklahoma from last November over its opioid marketing there. New York said J&J manufactured opioid products in the state including Nucynta and the fentanyl patch Duragesic, and received multiple U.S. Food and Drug Administration letters challenging its Duragesic marketing claims. The state also said J&J’s “Norman Poppy,” developed in 1994, once accounted for as much as 80% of the global supply for oxycodone raw materials. Oxycodone is the main ingredient in OxyContin, made by the now-bankrupt Purdue Pharma LP. The U.S. Centers for Disease Control and Prevention has said opioids have contributed to more than 400,000 deaths since 1997. J&J was charged with violating two New York insurance laws, with civil penalties of up to $5,000 per violation. Our Standards: The Thomson Reuters Trust Principles. REUTERS NEWS NOW Subscribe to our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox. Submit MORE FROM REUTERS Apps Newsletters Advertise with Us Advertising Guidelines Cookies Terms of Use Privacy All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. © 2020 Reuters. All Rights Reserved. Cookie-Einverständnis